Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urologica e Nefrologica 2019 December;71(6) > Minerva Urologica e Nefrologica 2019 December;71(6):590-6



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


ORIGINAL ARTICLE   Free accessfree

Minerva Urologica e Nefrologica 2019 December;71(6):590-6

DOI: 10.23736/S0393-2249.19.03566-5


lingua: Inglese

Combined reporting of surgical quality, cancer control and functional outcomes of robot-assisted radical cystectomy with intracorporeal orthotopic neobladder into a novel trifecta

Aldo BRASSETTI 1 , Gabriele TUDERTI 1, Umberto ANCESCHI 1, Mariaconsiglia FERRIERO 1, Salvatore GUAGLIANONE 1, Michele GALLUCCI 2, Giuseppe SIMONE 1

1 Department of Urology, Regina Elena National Cancer Institute, Rome, Italy; 2 Department of Urology, Sapienza University, Rome, Italy

BACKGROUND: To optimize outcomes reporting after robot-assisted radical cystectomy (RARC) with intracorporeal orthotopic neobladder (iON), we propose a novel trifecta, aimed to overcome the available pentafectas that neglect functional outcomes.
METHODS: A retrospective analysis of prospectively maintained RARC-iON dataset was performed. Baseline demographic, clinical, pathologic, perioperative and follow-up data were collected. Trifecta was defined as the coexistence of daytime urinary continence, Clavien-Dindo ≥3 complication-free and recurrence-free status, all assessed at 1 year. Kaplan-Meier method assessed the role of trifecta achievement in predicting overall survival (OS) probabilities. Univariable and multivariable regression analyses identified predictors of trifecta achievement. The predictive accuracy of trifecta and other pentafectas on 3-year OS probability was plotted with receiver operating characteristic (ROC) analyses.
RESULTS: The trifecta rate was 53% while 62% and 47% of patients achieved the University of Southern California (USC-P) and PROMETRICS group (PROM-P) pentafectas, respectively. On tertile analysis, both trifecta (P=0.011) and USC-P (P=0.043) rates significantly increased with surgical experience, while PROM-P did not (P=0.204). On ROC analysis, trifecta was the only significant predictor of 3-year OS probability (AUC=0.69, 95% CI:0.55-0.82; P=0.018). On Kaplan-Meier analysis, patients achieving trifecta displayed significantly higher OS probability (P=0.032); adjusted for covariates, each incremental case was associated with a 2% increased probability (OR: 1.02) of achieving trifecta on multivariable regression model.
CONCLUSIONS: Learning curve in RARC-iON has a significant impact on achievement of trifecta. This tool combines accurate measurement of surgical proficiency with an independent predictive value in assessing 3-year OS probabilities.

KEY WORDS: Urinary bladder neoplasms; Urinary incontinence; Urinary diversion; Cystectomy; Robotic surgical procedures; Survival

inizio pagina